Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estradiol's Impact on PrEP Nucleotides in the Lower GI Tract
NCT03917420Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early Follicular Phase. Started Mar 2019; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03917420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917420.